Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.19Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2025
|% Change Since: 4.88%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, financial stability, and strategic partnerships, particularly in autoimmune and inflammatory disease areas. However, challenges remain with potential placebo effects in trials and limited revenue growth in the near term. Overall, the call reflects a cautiously optimistic outlook with a balance of strategic achievements and ongoing challenges.Company Guidance
During Nektar Therapeutics' Fourth Quarter 2024 financial results conference call, the company provided several key metrics and forward-looking statements. Nektar completed enrollment for its Nektar-sponsored Phase 2b studies: the 400-patient REZOLVE-AD trial for atopic dermatitis and the 90-patient REZOLVE-AA study for alopecia areata. Results from these trials are expected in the second and fourth quarters of 2025, respectively. The company also announced a collaboration with TrialNet for a Phase 2 trial of REZPEG in 66 patients with new onset type 1 diabetes. Financially, Nektar ended 2024 with $269.1 million in cash and investments, projecting this runway to extend into the fourth quarter of 2026, and anticipates 2025 revenue between $40 million and $50 million. Additionally, they announced plans for an IND submission for their preclinical program NKTR-0165 in the second half of 2025.Successful Enrollment and Study Progress
Nektar completed enrollment for two Phase 2b studies in atopic dermatitis (REZOLVE-AD) and alopecia areata (REZOLVE-AA) on schedule, demonstrating strong interest from patients and physicians. Topline data for atopic dermatitis is expected in Q2 2025 and for alopecia areata in Q4 2025.
Financial Stability
Nektar ended 2024 with $269 million in cash and investments and a cash runway extending into Q4 2026, ensuring financial stability for ongoing and future projects.
Fast Track Designation for REZPEG
REZPEG received Fast Track designation from the FDA for the treatment of moderate to severe atopic dermatitis, facilitating a closer collaboration with the agency for future development plans.
Collaboration with TrialNet for Type 1 Diabetes Study
Nektar partnered with TrialNet to conduct a Phase 2 trial of REZPEG in type 1 diabetes, aiming to preserve insulin-producing beta cells and improve patient outcomes.
Advancement in Preclinical Programs
The company is advancing its TNFR2 agonist antibody program, NKTR-0165, with plans for an IND submission in H2 2025, and developing a pipeline of bispecific molecules pairing TNFR2 agonism with other targets.
---
NKTR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NKTR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 12, 2025 | $0.82 | $0.82 | 0.00% |
| Nov 07, 2024 | $1.37 | $1.40 | +2.19% |
| Aug 08, 2024 | $1.21 | $1.11 | -8.26% |
| May 09, 2024 | $1.60 | $1.76 | +10.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Nektar Therapeutics (NKTR) report earnings?
Nektar Therapeutics (NKTR) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Nektar Therapeutics (NKTR) earnings time?
Nektar Therapeutics (NKTR) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NKTR EPS forecast?
NKTR EPS forecast for the fiscal quarter 2025 (Q1) is -0.17.
---